• ქართული
  • English
  • Takeda sells dry eye drug to Novartis to help cut debt

    Takeda Pharmaceutical Co Ltd agreed to sell its dry eye drug to Swiss drugmaker Novartis AG for $3.4 billion and potential milestone payments of up to $1.9 billion, in the first divestment since its takeover of Britain’s Shire.

    Market Quotes by TradingView